Cargando…
Cost‐per‐diagnosis as a metric for monitoring cost‐effectiveness of HIV testing programmes in low‐income settings in southern Africa: health economic and modelling analysis
INTRODUCTION: As prevalence of undiagnosed HIV declines, it is unclear whether testing programmes will be cost‐effective. To guide their HIV testing programmes, countries require appropriate metrics that can be measured. The cost‐per‐diagnosis is potentially a useful metric. METHODS: We simulated a...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615491/ https://www.ncbi.nlm.nih.gov/pubmed/31287620 http://dx.doi.org/10.1002/jia2.25325 |
_version_ | 1783433371357020160 |
---|---|
author | Phillips, Andrew N Cambiano, Valentina Nakagawa, Fumiyo Bansi‐Matharu, Loveleen Wilson, David Jani, Ilesh Apollo, Tsitsi Sculpher, Mark Hallett, Timothy Kerr, Cliff van Oosterhout, Joep J Eaton, Jeffrey W Estill, Janne Williams, Brian Doi, Naoko Cowan, Frances Keiser, Olivia Ford, Deborah Hatzold, Karin Barnabas, Ruanne Ayles, Helen Meyer‐Rath, Gesine Nelson, Lisa Johnson, Cheryl Baggaley, Rachel Fakoya, Ade Jahn, Andreas Revill, Paul |
author_facet | Phillips, Andrew N Cambiano, Valentina Nakagawa, Fumiyo Bansi‐Matharu, Loveleen Wilson, David Jani, Ilesh Apollo, Tsitsi Sculpher, Mark Hallett, Timothy Kerr, Cliff van Oosterhout, Joep J Eaton, Jeffrey W Estill, Janne Williams, Brian Doi, Naoko Cowan, Frances Keiser, Olivia Ford, Deborah Hatzold, Karin Barnabas, Ruanne Ayles, Helen Meyer‐Rath, Gesine Nelson, Lisa Johnson, Cheryl Baggaley, Rachel Fakoya, Ade Jahn, Andreas Revill, Paul |
author_sort | Phillips, Andrew N |
collection | PubMed |
description | INTRODUCTION: As prevalence of undiagnosed HIV declines, it is unclear whether testing programmes will be cost‐effective. To guide their HIV testing programmes, countries require appropriate metrics that can be measured. The cost‐per‐diagnosis is potentially a useful metric. METHODS: We simulated a series of setting‐scenarios for adult HIV epidemics and ART programmes typical of settings in southern Africa using an individual‐based model and projected forward from 2018 under two policies: (i) a minimum package of “core” testing (i.e. testing in pregnant women, for diagnosis of symptoms, in sex workers, and in men coming forward for circumcision) is conducted, and (ii) core‐testing as above plus additional testing beyond this (“additional‐testing”), for which we specify different rates of testing and various degrees to which those with HIV are more likely to test than those without HIV. We also considered a plausible range of unit test costs. The aim was to assess the relationship between cost‐per‐diagnosis and the incremental cost‐effectiveness ratio (ICER) of the additional‐testing policy. The discount rate used in the base case was 3% per annum (costs in 2018 U.S. dollars). RESULTS: There was a strong graded relationship between the cost‐per‐diagnosis and the ICER. Overall, the ICER was below $500 per‐DALY‐averted (the cost‐effectiveness threshold used in primary analysis) so long as the cost‐per‐diagnosis was below $315. This threshold cost‐per‐diagnosis was similar according to epidemic and programmatic features including the prevalence of undiagnosed HIV, the HIV incidence and a measure of HIV programme quality (the proportion of HIV diagnosed people having a viral load <1000 copies/mL). However, restricting to women, additional‐testing did not appear cost‐effective even at a cost‐per‐diagnosis of below $50, while restricting to men additional‐testing was cost‐effective up to a cost‐per‐diagnosis of $585. The threshold cost per diagnosis for testing in men to be cost‐effective fell to $256 when the cost‐effectiveness threshold was $300 instead of $500, and to $81 when considering a discount rate of 10% per annum. CONCLUSIONS: For testing programmes in low‐income settings in southern African there is an extremely strong relationship between the cost‐per‐diagnosis and the cost‐per‐DALY averted, indicating that the cost‐per‐diagnosis can be used to monitor the cost‐effectiveness of testing programmes. |
format | Online Article Text |
id | pubmed-6615491 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-66154912019-07-16 Cost‐per‐diagnosis as a metric for monitoring cost‐effectiveness of HIV testing programmes in low‐income settings in southern Africa: health economic and modelling analysis Phillips, Andrew N Cambiano, Valentina Nakagawa, Fumiyo Bansi‐Matharu, Loveleen Wilson, David Jani, Ilesh Apollo, Tsitsi Sculpher, Mark Hallett, Timothy Kerr, Cliff van Oosterhout, Joep J Eaton, Jeffrey W Estill, Janne Williams, Brian Doi, Naoko Cowan, Frances Keiser, Olivia Ford, Deborah Hatzold, Karin Barnabas, Ruanne Ayles, Helen Meyer‐Rath, Gesine Nelson, Lisa Johnson, Cheryl Baggaley, Rachel Fakoya, Ade Jahn, Andreas Revill, Paul J Int AIDS Soc Research Articles INTRODUCTION: As prevalence of undiagnosed HIV declines, it is unclear whether testing programmes will be cost‐effective. To guide their HIV testing programmes, countries require appropriate metrics that can be measured. The cost‐per‐diagnosis is potentially a useful metric. METHODS: We simulated a series of setting‐scenarios for adult HIV epidemics and ART programmes typical of settings in southern Africa using an individual‐based model and projected forward from 2018 under two policies: (i) a minimum package of “core” testing (i.e. testing in pregnant women, for diagnosis of symptoms, in sex workers, and in men coming forward for circumcision) is conducted, and (ii) core‐testing as above plus additional testing beyond this (“additional‐testing”), for which we specify different rates of testing and various degrees to which those with HIV are more likely to test than those without HIV. We also considered a plausible range of unit test costs. The aim was to assess the relationship between cost‐per‐diagnosis and the incremental cost‐effectiveness ratio (ICER) of the additional‐testing policy. The discount rate used in the base case was 3% per annum (costs in 2018 U.S. dollars). RESULTS: There was a strong graded relationship between the cost‐per‐diagnosis and the ICER. Overall, the ICER was below $500 per‐DALY‐averted (the cost‐effectiveness threshold used in primary analysis) so long as the cost‐per‐diagnosis was below $315. This threshold cost‐per‐diagnosis was similar according to epidemic and programmatic features including the prevalence of undiagnosed HIV, the HIV incidence and a measure of HIV programme quality (the proportion of HIV diagnosed people having a viral load <1000 copies/mL). However, restricting to women, additional‐testing did not appear cost‐effective even at a cost‐per‐diagnosis of below $50, while restricting to men additional‐testing was cost‐effective up to a cost‐per‐diagnosis of $585. The threshold cost per diagnosis for testing in men to be cost‐effective fell to $256 when the cost‐effectiveness threshold was $300 instead of $500, and to $81 when considering a discount rate of 10% per annum. CONCLUSIONS: For testing programmes in low‐income settings in southern African there is an extremely strong relationship between the cost‐per‐diagnosis and the cost‐per‐DALY averted, indicating that the cost‐per‐diagnosis can be used to monitor the cost‐effectiveness of testing programmes. John Wiley and Sons Inc. 2019-07-09 /pmc/articles/PMC6615491/ /pubmed/31287620 http://dx.doi.org/10.1002/jia2.25325 Text en © 2019 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Phillips, Andrew N Cambiano, Valentina Nakagawa, Fumiyo Bansi‐Matharu, Loveleen Wilson, David Jani, Ilesh Apollo, Tsitsi Sculpher, Mark Hallett, Timothy Kerr, Cliff van Oosterhout, Joep J Eaton, Jeffrey W Estill, Janne Williams, Brian Doi, Naoko Cowan, Frances Keiser, Olivia Ford, Deborah Hatzold, Karin Barnabas, Ruanne Ayles, Helen Meyer‐Rath, Gesine Nelson, Lisa Johnson, Cheryl Baggaley, Rachel Fakoya, Ade Jahn, Andreas Revill, Paul Cost‐per‐diagnosis as a metric for monitoring cost‐effectiveness of HIV testing programmes in low‐income settings in southern Africa: health economic and modelling analysis |
title | Cost‐per‐diagnosis as a metric for monitoring cost‐effectiveness of HIV testing programmes in low‐income settings in southern Africa: health economic and modelling analysis |
title_full | Cost‐per‐diagnosis as a metric for monitoring cost‐effectiveness of HIV testing programmes in low‐income settings in southern Africa: health economic and modelling analysis |
title_fullStr | Cost‐per‐diagnosis as a metric for monitoring cost‐effectiveness of HIV testing programmes in low‐income settings in southern Africa: health economic and modelling analysis |
title_full_unstemmed | Cost‐per‐diagnosis as a metric for monitoring cost‐effectiveness of HIV testing programmes in low‐income settings in southern Africa: health economic and modelling analysis |
title_short | Cost‐per‐diagnosis as a metric for monitoring cost‐effectiveness of HIV testing programmes in low‐income settings in southern Africa: health economic and modelling analysis |
title_sort | cost‐per‐diagnosis as a metric for monitoring cost‐effectiveness of hiv testing programmes in low‐income settings in southern africa: health economic and modelling analysis |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615491/ https://www.ncbi.nlm.nih.gov/pubmed/31287620 http://dx.doi.org/10.1002/jia2.25325 |
work_keys_str_mv | AT phillipsandrewn costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT cambianovalentina costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT nakagawafumiyo costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT bansimatharuloveleen costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT wilsondavid costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT janiilesh costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT apollotsitsi costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT sculphermark costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT halletttimothy costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT kerrcliff costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT vanoosterhoutjoepj costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT eatonjeffreyw costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT estilljanne costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT williamsbrian costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT doinaoko costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT cowanfrances costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT keiserolivia costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT forddeborah costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT hatzoldkarin costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT barnabasruanne costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT ayleshelen costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT meyerrathgesine costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT nelsonlisa costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT johnsoncheryl costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT baggaleyrachel costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT fakoyaade costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT jahnandreas costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis AT revillpaul costperdiagnosisasametricformonitoringcosteffectivenessofhivtestingprogrammesinlowincomesettingsinsouthernafricahealtheconomicandmodellinganalysis |